Freedom: Viridian Therapeutics Shares May Surge Nearly 100 % on FDA Decision for Thyroid Disease Treatment

Viridian Therapeutics is approaching a key milestone in its history: the FDA is expected to make a decision on June 30 regarding the approval of veligrotug, a drug for treating thyroid eye disease. Freedom analysts assess the approval prospects as high and note that the target price implies an upside potential of about 97 %.

Viridian Therapeutics is a US biotechnology company developing treatments for autoimmune and rare diseases. Its most promising asset is veligrotug, a candidate therapy for thyroid eye disease — a severe eye condition associated with thyroid dysfunction.

Freedom analysts believe veligrotug could disrupt the de facto monopoly of Amgen’s TEPEZZA in this market. In the THRIVE and THRIVE‑2 clinical trials, the drug demonstrated compelling results in both patients with active and chronic forms of the disease.

An additional advantage of the new drug could be a more convenient treatment regimen. The standard veligrotug course requires fewer intravenous infusions compared with the competitor, and therapeutic effects were observed in some patients as early as three weeks after the first dose.

Freedom believes that the absence of major safety concerns and the drug’s Breakthrough Therapy and Priority Review designations boost the likelihood of a positive regulatory decision. A successful approval could mark Viridian’s first commercial success and significantly reshape the company’s investment profile.

Not an individual investment recommendation.